Alex Gariti
Biographic Data
| ID | 9596267 |
|---|---|
| NAME | Alex Gariti |
| GIVEN NAMES | Alex |
| FAMILY NAME | Gariti |
| SIGNATURE | GARITI A |
| AFFILIATIONS | Baylor College of Medicine |
| ORCID | 0000-0002-0655-2055 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Slide the scale back
Decision-making capacity (DMC) assessments determine whether patients may authorize medical interventions, yet the prevailing sliding-scale model, requiring greater certainty of capacity for higher-risk decisions, fails to account for the ethical implications of declaring a patient incapacitated. When patients are found to lack DMC, decision-making authority shifts to surrogate decision-makers, whose well-documented inaccuracy in predicting patie…
Harm reduction in paediatric off-label therapy
Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and…
No prominent works on this page.
Slide the scale back
Decision-making capacity (DMC) assessments determine whether patients may authorize medical interventions, yet the prevailing sliding-scale model, requiring greater certainty of capacity for higher-risk decisions, fails to account for the ethical implications of declaring a patient incapacitated. When patients are found to lack DMC, decision-making authority shifts to surrogate decision-makers, whose well-documented inaccuracy in predicting patie…
Harm reduction in paediatric off-label therapy
Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and…
Best interests (1 work) · Certainty (1 work) · Clinical Ethics (1 work) · Clinical judgment (1 work) · Cystic fibrosis (1 work) · Cystic Fibrosis Research Advances (1 work) · Cystic fibrosis transmembrane conductance regulator (1 work) · Disease (1 work) · Do no harm (1 work) · Ethics and Legal Issues in Pediatric Healthcare (1 work)